XML 74 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaboration and License Agreements - Performance Obligations (Details) - Collaborative Arrangement
9 Months Ended
Sep. 30, 2022
item
component
IDRx, Inc. | Director  
Performance Obligations  
Collaborative arrangement, material promises, number 2
Collaborative arrangement, material promises, combined into distinct performance obligation, number 1
Zai Lab (Shanghai) Co., Ltd.  
Performance Obligations  
Collaborative arrangement, material promises, number 3
Collaborative arrangement, material promises, combined into distinct performance obligation, number 2
Collaborative arrangement, material components, number | component 2
Roche, Collaboration (Pralsetnib) Agreement  
Performance Obligations  
Collaborative arrangement, material promises, number 1
Collaborative arrangement, material promises, manufacturing activities, term 24 months
Collaborative arrangement, material components, number | component 4
Roche, Collaboration and License (Immunotherapy) Agreement  
Performance Obligations  
Revenue, performance obligation, performance obligations, number 1
Roche, Collaboration and License (Immunotherapy) Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01  
Performance Obligations  
Revenue, remaining performance obligation, expected timing of satisfaction, period 3 years 3 months 18 days
Clementia  
Performance Obligations  
Collaborative arrangement, material promises, number 4
Revenue, performance obligation, performance obligations, number 3
C Stone  
Performance Obligations  
Collaborative arrangement, material promises, number 6
Collaborative arrangement, material components, number | component 2
Revenue, performance obligation, performance obligations, number 3